Small Molecules

In this video interview, Mike Rea explains why each drug needs its own launch strategy.

Emerging technologies are proving that small molecules aren't yesterday's news.

How is the field of antibody drug conjugates being reshaped?

Pharma wants to empower patients to make informed healthcare decisions, but patients also need to be protected from misinformation.

Manufacturers must look to ease the headaches associated with the manufacture of mRNA-based products.

A diverse range of malaria treatments will make all the difference in the prevention of resistance.

How the Drugs for Neglected Diseases Initiative and the Malaysian government partnered to tackle hep C with an affordable, effective cure.

Has pharma fully acknowledged the power of rapid-dissolve tablet technologies?

Precious metals-bearing catalysts are essential in some pharma processes – but, once they’re spent, they still hold value.

Eli Lilly’s Loxo Oncology has signed a deal with Yi Liu’s Kumquat Biosciences, targeting novel small molecules for immuno-oncology.